The successful candidate will lead compliance monitoring activities across Commercial, Medical Affairs, Clinical Development, Regulatory, Market Access, Patient Services, Finance, Human Resources, Legal, and other business functions to evaluate compliance risks, identify opportunities for improvement, and promote a culture of ethics and integrity. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.